Company intelligence / Profile preview

Currax Holdings

Morristown, New Jersey, United States

Ownership: Private
Employees: ~126
Development stage: Other

Overview

Currax Pharmaceuticals is a commercial-stage, specialty pharmaceutical company focused on acquiring and commercializing prescription drugs in underserved therapeutic areas, particularly central nervous system disorders including neurology, pain, and psychiatry. Its marketed products include Contrave (naltrexone + bupropion) for obesity, Onzetra Xsail (sumatriptan) and Treximet (sumatriptan + naproxen) for migraine, and Silenor (doxepin) for insomnia. The company continues to distribute and support these products through retail pharmacies and patient support programs.

Therapeutic areas: NeurologyEndocrinologyPsychiatry
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Currax Holdings.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Currax Holdings.

Explore the full profile